An official website of the United States government
Home
This neoplasm is not reportable.
ICD-O-3 Morphology
9898/1: Transient abnormal myelopiesis
Effective
2010 and later
Reportability
This neoplasm is not reportable
Primary Site(s)
No primary site specified
Primary site bone marrow (C421)
This hematopoietic disease is not reportable for the U.S.
Canada, refer to your specific province for reportability requirements.
This hematopoietic disease is not reportable for the U.S.
Canada, refer to your specific province for reportability requirements.
Abstractor Notes
Transient abnormal myelopoiesis (TAM) is part of the Secondary myeloid lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B7)
TAM manifests mainly in the peripheral blood. Severe cases affect the liver, spleen, pleura, and pericardium. Bone marrow involvement is usually mild.
TAM can be a life-threatening disease to an asymptomatic incidental finding.
TAM manifests mainly in the peripheral blood. Severe cases affect the liver, spleen, pleura, and pericardium. Bone marrow involvement is usually mild.
TAM can be a life-threatening disease to an asymptomatic incidental finding.
Alternate Names
Transient abnormal myelopoiesis associated with Down syndrome
Definition
Transient abnormal myelopoiesis (TAM) associated with Down syndrome is a unique disorder of newborns with Down syndrome that presents with clinical and morphological findings indistinguishable from those of acute myeloid leukemia. The blasts have morphological and immunological features of megakaryocytic lineage.
Definitive Diagnostic Methods
This data item does not apply
Genetics Data
This data item does not apply
Immunophenotyping
This data item does not apply
Corresponding ICD-10 Codes (Cause of Death codes only)
D47.7 Other specified neoplasms of uncertain or unknown behavior of lymphoid, hematopoietic, and related tissue
Corresponding ICD-10-CM Codes (U.S. only)
D47.Z9 Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue (effective October 01, 2015)
Signs and Symptoms
Cholestatic jaundice
Hepatomegaly (severe disease only)
Leukocytosis
Pleural/pericardial effusion (several disease only)
Splenomegaly (severe disease only)
Vesiculopapular skin rash (severe disease only)
Diagnostic Exams
Epidemiology and Mortality
25-30% of newborns with Down Syndrome have TAM
TAM is the most common leukemia in neonates
Sources
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https://publications.iarc.who.int/637.
Section: Myeloid proliferations associated with Down syndrome
Pages: Part A: 182-183
Section: Myeloid proliferations associated with Down syndrome
Pages: Part A: 182-183
International Classification of Diseases for Oncology, 3rd edition (including revisions). Geneva: World Health Organization, 2001, 2011, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
